Since we demonstrated that PAK6 suppression can inhibit CML cell proliferation and survival, we wanted to investigate additional oncogenic mechanisms governed by PAK6 in CML. The gene discussed is PAK6; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.